Related Experiment Video

Updated: Jun 7, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

[Targeting insulin-like growth factors in the treatment of cancer]

D Moro-Sibilot1, M Coudurier, S Lantuejoul

  • 1UF oncologie thoracique, pole de médecine aiguë communautaire, CHU Albert-Michallon, BP 217, 38043 Grenoble cedex 9, France. DMoro.pneumo@chu-grenoble.fr

Revue Des Maladies Respiratoires
|October 23, 2010
PubMed
Abstract

Insights

Targeting the insulin-like growth factor I receptor (IGF-IR) shows promise for cancer treatment. Early studies indicate potential benefits, especially in non-small-cell lung cancer (NSCLC), warranting further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • The insulin-like growth factor I receptor (IGF-IR) pathway is implicated in cancer progression, survival, and therapeutic resistance.
  • Extensive preclinical data supports IGF-IR targeting as a cancer therapy strategy.
  • Early clinical trials have demonstrated an acceptable safety profile and target engagement.

Purpose:

  • To evaluate the therapeutic potential of targeting the IGF-IR pathway in cancer treatment.
  • To assess the efficacy and safety of IGF-IR inhibitors in clinical settings.

Summary:

  • Preclinical research and early clinical trials suggest that targeting the IGF-IR pathway is a viable strategy for cancer therapy.
  • Phase I trials showed single-agent activity, and a Phase II study indicated improved outcomes for non-small-cell lung cancer (NSCLC) when an anti-IGF-1R antibody was combined with chemotherapy.
  • These findings support continued investigation into IGF-IR targeting, particularly for NSCLC.

Impact:

  • IGF-IR targeting represents a promising therapeutic avenue, with over two dozen compounds developed and ongoing clinical trials.
  • The findings encourage further development and clinical evaluation of IGF-IR-targeted therapies for various cancers, including NSCLC.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...